Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ECYT's Cash to Debt is ranked higher than
86% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ECYT: No Debt )
ECYT' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: No Debt

Equity to Asset 0.54
ECYT's Equity to Asset is ranked higher than
60% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. ECYT: 0.54 )
ECYT' s 10-Year Equity to Asset Range
Min: -3.01   Max: 0.86
Current: 0.54

-3.01
0.86
F-Score: 2
Z-Score: 5.38
M-Score: -1.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -28.27
ECYT's Operating margin (%) is ranked lower than
51% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. ECYT: -28.27 )
ECYT' s 10-Year Operating margin (%) Range
Min: -20228.8   Max: -28.27
Current: -28.27

-20228.8
-28.27
Net-margin (%) -27.80
ECYT's Net-margin (%) is ranked lower than
51% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. ECYT: -27.80 )
ECYT' s 10-Year Net-margin (%) Range
Min: -21220.94   Max: -27.8
Current: -27.8

-21220.94
-27.8
ROE (%) -20.44
ECYT's ROE (%) is ranked lower than
51% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ECYT: -20.44 )
ECYT' s 10-Year ROE (%) Range
Min: -35.75   Max: -17.37
Current: -20.44

-35.75
-17.37
ROA (%) -11.07
ECYT's ROA (%) is ranked higher than
51% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. ECYT: -11.07 )
ECYT' s 10-Year ROA (%) Range
Min: -94.72   Max: -8.08
Current: -11.07

-94.72
-8.08
ROC (Joel Greenblatt) (%) -477.78
ECYT's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. ECYT: -477.78 )
ECYT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3487.09   Max: -477.78
Current: -477.78

-3487.09
-477.78
EBITDA Growth (%) -71.30
ECYT's EBITDA Growth (%) is ranked lower than
59% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. ECYT: -71.30 )
ECYT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -70.2
Current: -71.3

EPS Growth (%) -71.60
ECYT's EPS Growth (%) is ranked lower than
58% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. ECYT: -71.60 )
ECYT' s 10-Year EPS Growth (%) Range
Min: 0   Max: -70.5
Current: -71.6

» ECYT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ECYT Guru Trades in Q1 2013

Jim Simons 97,100 sh (-48.2%)
» More
Q2 2013

ECYT Guru Trades in Q2 2013

Jim Simons 26,500 sh (-72.71%)
» More
Q3 2013

ECYT Guru Trades in Q3 2013

RS Investment Management 480,300 sh (New)
Jim Simons 70,400 sh (+165.66%)
» More
Q4 2013

ECYT Guru Trades in Q4 2013

Paul Tudor Jones 16,744 sh (New)
RS Investment Management 510,400 sh (+6.27%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.07%$3.8 - $8.35 $ 18.15173%0
George Soros 2012-03-31 Add 53.85%0.03%$3.36 - $5.89 $ 18.15389%1000000
George Soros 2011-12-31 Add 766.67%0.1%$3.06 - $11.3 $ 18.15103%650000
George Soros 2011-09-30 New Buy0.01%$9.36 - $14.65 $ 18.1554%75000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.30
ECYT's P/B is ranked lower than
67% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. ECYT: 7.30 )
ECYT' s 10-Year P/B Range
Min: 0.97   Max: 11.55
Current: 7.3

0.97
11.55
P/S 10.10
ECYT's P/S is ranked lower than
76% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. ECYT: 10.10 )
ECYT' s 10-Year P/S Range
Min: 5.19   Max: 1100
Current: 10.1

5.19
1100
EV-to-EBIT 1000.00
ECYT's EV-to-EBIT is ranked lower than
79% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. ECYT: 1000.00 )
ECYT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 1000

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.40
ECYT's Price/Net Cash is ranked lower than
53% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. ECYT: 13.40 )
ECYT' s 10-Year Price/Net Cash Range
Min: 1.22   Max: 7.91
Current: 13.4

1.22
7.91
Price/Net Current Asset Value 12.30
ECYT's Price/Net Current Asset Value is ranked lower than
57% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. ECYT: 12.30 )
ECYT' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 7.22
Current: 12.3

1.22
7.22
Price/Tangible Book 7.40
ECYT's Price/Tangible Book is ranked lower than
69% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. ECYT: 7.40 )
ECYT' s 10-Year Price/Tangible Book Range
Min: 1.19   Max: 4.38
Current: 7.4

1.19
4.38
Price/Median PS Value 1.00
ECYT's Price/Median PS Value is ranked higher than
65% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. ECYT: 1.00 )
ECYT' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 37.6
Current: 1

0.58
37.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:9EY.Germany
Endocyte, Inc. is a biopharmaceutical Company. It targets therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnose.
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
comment on ECYT Mar 06 2013 
Merck: Ready to Rise on New Drugs Apr 18 2012 
3.13 Jan 30 2012 
Lots of insider trad Jan 13 2012 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide